Skulimowska I, Sosniak J, Gonka M, Szade A, Jozkowicz A, Szade K (2021) The biology of hematopoietic stem cells and its clinical implications. FEBS J 16192. doi: 10.1111/febs.16192
Objective: To review the opportunities and challenges of recent findings to improve the clinical use of hematopoietic stem cells (HSCs)
Summary: The authors describe new methods of HSC mobilization and conditioning for transplantation and highlight research that may lead to solutions for the limitations of HSC transplantation
Dose: See (Palchaudhuri, R., 2016, https://atsbio.com/tt16q3-article1/)
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, & Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. (2019) Nat Commun 10:617. doi: 10.1038/s41467-018-08201-x
Objective: To investigate a safe and effective method for hematopoietic stem cell transplantation.
Summary: CD117-ADC selectively targets hematopoietic stem cells yet does not cause clinically significant side-effects.
Dose: The CD117-ADC was prepared by combining biotinylated anti-CD117 (clone 2B8) with Streptavidin–ZAP. A dose of 1.5 mg/kg of CD117-ADC (~12 µg Streptavidin-ZAP) optimally resulted in depletion of >99% of immunophenotypic and functional HSCs.